STAT+: Pharma’s reputation with patient groups dips again, mostly due to pricing issues
STAT
APRIL 28, 2025
For the second consecutive year, the pharmaceutical industry saw its reputation slip among patient advocacy groups, largely due to ongoing concerns over pricing issues, according to a new survey. Of more than 2,500 groups queried, 56% reported the industry had an “excellent” or “good” reputation as it goes about the business of developing and providing medicines.
Let's personalize your content